Revive Therapeutics
  • Home
  • About
    • Management Team
    • Advisory Clinical Team
    • Board of Directors
  • Pipeline
    • Infectious Diseases
    • Intellectual Property
  • Investor
  • News
  • Contact
Select Page

Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures

by rvvadmin | May 20, 2026 | 2026

Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a potential franchise asset for infectious diseases, nerve-agent exposure, future pandemics and medical countermeasure stockpiling TORONTO, ON / May...

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

by rvvadmin | Mar 11, 2026 | 2026

Patent momentum expands Revive’s bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications TORONTO, ON /  March 11, 2026 / Revive Therapeutics Ltd. (“Revive” or the...

NEWS

2022

2021

2020

2019

Click Here for more news.
(Forwards to SEDAR website)

Privacy Policy

Disclaimer

  • Facebook
  • X
  • Instagram
© COPYRIGHT 2025. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.